Italia markets close in 4 hours 51 minutes

FTSE MIB
34.702,32
+363,00(+1,06%)
Dow Jones
39.387,76
+331,36(+0,85%)
Nasdaq
16.346,26
+43,46(+0,27%)
Nikkei 225
38.229,11
+155,13(+0,41%)
Petrolio
79,80
+0,54(+0,68%)
Bitcoin EUR
58.479,09
+1.835,10(+3,24%)

NVCR May 2024 17.500 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

3,7500

0,0000

(0,00%)

In data: 03:50PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in